Frequency Therapeutics Investor Event: Preparing for FX-322 Phase 2b Data
Frequency Therapeutics hosted a virtual investor event on December 13, 2022. The primary focus was FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). Company management reviewed the FX-322 Phase 2b study design, the patient populations targeted for enrollment, pre-specified speech perception endpoints, and the potential FX-322 commercial market opportunity. Key opinion leaders (KOLs) also provided insight into the potential impact of a pharmaceutical intervention for patients with SNHL, how a medicine for cochlear regeneration may fit with currently available hearing devices, and the clinical significance of speech perception on overall hearing.
SVP, Strategic Marketing and New Product Planning
Chief Development Officer
Professor, Otolaryngology and Communication Sciences, Medical College of Wisconsin
Professor of Otology & Neurotology at St. Louis University and SSM Health